Communiqués Celltrion, Inc.

Actions

A068270

KR7068270008

Recherche biotechnologique et médicale

Cours en clôture Korea S.E. 12/08/2026			Varia. 5j.	Varia. 1 janv.
202 000,00 ^KRW	-4,04%		+6,15%	+17,18%

04/08	Celltrion dépose un amendement pour l'essai de phase 3 du CT-P44, biosimilaire contre le myélome	MT
24/07	Celltrion dépose une demande d'autorisation de mise sur le marché auprès de l'EMA pour le CT-P55, biosimilaire du Cosentyx	MT

Communiqués

27/07	Celltrion : Reports Q2 2026 Revenue of KRW 1.3937Tn and Operating Profit of KRW 451.8Bn; Record Quarterly Revenue as New Product Growth and Cost Improvements Boost Profitability	PU
07/07	Celltrion : Vegzelma completes formulary listings with two major U.S. PBMs, expanding reimbursement access to drive further U.S. growth	PU
03/07	Celltrion : Reports Preliminary Q2 2026 Revenue of KRW 1.3Tn and Operating Profit of KRW 430Bn… Achieving Record-High Second-Quarter Performance, Raising Expectations for Full-Year Target Outperformance	PU
24/03	Celltrion : Announces KRW 1.2Tn Expansion of New DS Production Facilities in Songdo; Adds 180,000L of DS capacity, bringing total capacity to 570,000L	PU
17/03	Celltrion : signs supply agreement with a global biopharma worth up to KRW 375.4 billion, reflecting recognition of product quality and manufacturing productivity, and accelerating CDMO growth	PU
11/03	Celltrion : launches Remsima IV liquid formulation in Europe, securing new competitiveness to lead the global infliximab market	PU
06/03	Celltrion to expand treasury share cancellation to 9.11 million shares: Prioritizing shareholder value amid heightened market uncertainty	PU
19/02	Celltrion : New ECCO data show subcutaneous (SC) infliximab (Remsima™ SC) effectively recaptures and maintains disease control after drug holiday	PU
12/02	Celltrion : to Submit Approx KRW 1.46Tn Treasury Share Cancellation Proposal to Shareholders’ Meeting; To Amend Articles Ahead of Commercial Act Revision to Enhance Transparency and Shareholder Value	PU
05/02	Celltrion : Reports Record-High Annual Revenue of KRW 4.1625Tn and Operating Profit of KRW 1.1685Tn in 2025… Signaling Continued Strong Growth Backed by High-Margin Newer Portfolio	PU
08/01	Celltrion And Sandoz Launch Their Aflibercept Biosimilars In Europe	AQ
05/11	FDA Grants Interchangeability Designation To Fresenius Kabi's And Celltrion's Denosumab Biosimilars	AQ
14/10/25	Celltrion Announces Launch Of AVTOZMA® (Tocilizumab-anoh) Intravenous Formulation In The United States	AQ
16/06/25	Celltrion : announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients	PU
12/05/25	Celltrion : Investor Presentation May & June 2025	PU
29/04/25	Celltrion Adalimumab Biosimilar Granted Interchangeability Designation	AQ
28/03/25	Celltrion's STEQEYMA, now added to the Costco Member Prescription Program	AQ
28/03/25	Celltrion Wins Costco Formulary Listing For Its Recently Launched Ustekinumab	AQ
26/03/25	Celltrion Launches STEQEYMA® (ustekinumab-stba) In The United States	AQ
10/03/25	U.S. FDA approves Celltrion's OMLYCLO as the first and only biosimilar with interchangeability designation referencing XOLAIR	AQ
06/03/25	Celltrion : Investor Presentation March & April 2025	PU
25/02/25	Celltrion : FY2024, 4Q24 Earning Release Celltrion Inc.	PU
24/02/25	Celltrion Receives EC Approval for Avtozma, a Biosimilar to RoActemra	AQ
31/01/25	Amgen And Celltrion Settle Denosumab BPCIA Case	AQ
09/01/25	FDA Approves Celltrion's STEQEYMA (Ustekinumab-stba)	AQ